T cell apoptosis inducer and method therefore

Patent metadata

Field	Value
Publication number	US-9339055-B2
Application number	US-201113167483-A
Country	US
Kind code	B2
Filing date	Jun 23, 2011
Priority date	Mar 4, 2005
Publication date	May 17, 2016
Grant date	May 17, 2016

Abstract

An inducer of T cell apoptosis and a health food for inducing T cell apoptosis comprising as an active ingredient of a lactic acid bacterium belonging to the genus Lactobacillus or the genus Bifidobacterium are disclosed. Particularly preferred lactic acid bacteria belonging to the genus Lactobacillus or the genus Bifidobacterium are Lactobacillus acidophilus L-92 (FERM BP-4981), Lactobacillus amylovorus CP1750 (FERM BP-10532), Bifidobacterium catenulatum CP2829 (FERM BP-10533) and Bifidobacterium longum CP760 (FERM BP-10531). The inducer of T cell apoptosis of the invention is useful in the prevention and cure of a disease such as an organ-specific autoimmune disease or type I allergy.

First claim

The invention claimed is:

1. A method for inducing T cell apoptosis comprising:
administering to a subject in need thereof a biologically pure lactic acid bacterium belonging to the genus Lactobacillus or the genus Bifidobacterium as an active ingredient and a carrier, wherein the biologically pure lactic acid bacterium is selected from the group consisting of Lactobacillus acidophilus strain FERM BP-4981 , Lactobacillus amylovorus strain FERM BP-10532, Bifidobacterium catenulatum strain FERM BP-10533 and Bifidobacterium longum strain FERM BP-10531.

2. The method according to claim 1 , wherein the active ingredient comprising the biologically pure lactic acid bacterium selected from the group consisting of Lactobacillus acidophilus strain FERM BP-4981 , Lactobacillus amylovorus strain FERM BP-10532, Bifidobacterium catenulatum strain FERM BP-10533 and Bifidobacterium longum strain FERM BP-10531 is in a health food.

3. The method according to claim 1 , wherein the biologically pure lactic acid bacterium is orally administered.

4. The method according to claim 1 , wherein Th2 cell apoptosis is induced.

5. The method according to claim 1 , wherein Th1 cell apoptosis is induced.

6. The method according to claim 1 , wherein both Th1 cell and Th2 cell apoptosis is induced.

7. The method according to claim 1 , wherein said method further involves a decrease of Il-4 production.

8. The method according to claim 1 , wherein apoptosis in antigen-specific T-cells is induced.

9. The method according to claim 1 , wherein apoptosis in spleen and mesenteric lymph nodes is induced.

10. A biologically pure lactic acid bacterium, Lactobacillus amylovorus strain FERM BP-10532.

11. A biologically pure lactic acid bacterium, Bifidobacterium catenulatum strain FERM BP-10533.

12. A biologically pure lactic acid bacterium, Bifidobacterium longum strain FERM BP-10531.

Assignees

• Fujiwara Shigeru
• Kanzato Hiroki
• Hachimura Satoshi
• Asahi Group Holdings Ltd

Inventors

• Fujiwara Shigeru
• Kanzato Hiroki
• Hachimura Satoshi

Classifications

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P5/14

  of the thyroid hormones, e.g. T3, T4 · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title